Compare Docusign Inc (DOCU) vs Moderna, Inc. (MRNA) Price & Performance

DOCU trades at $57.89, down 2.93% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $1.09 exceeding expectations. Revenue growth remains steady, reaching $2.98B in 2025, while profitability improved significantly with a net income margin of 35.87%.

The outlook is mixed with solid fundamentals supporting long-term growth, but valuation multiples appear elevated. Key risks include competitive pressures and market volatility. Analyst consensus is cautious with a $55.40 price target below current levels, suggesting limited near-term upside despite positive operational trends.

Moderna (MRNA) trades at $63.57, up 6.29% on the day, reflecting positive momentum following FDA approval of its mRNA flu vaccine, mFLUSIVA, for adults 50 and older. The stock exhibits a bullish technical outlook with moving averages supporting upward movement, though RSI levels suggest potential overbought conditions. Fundamentally, revenue has declined from pandemic peaks, with 2025 revenue at $1.92B and a net loss of -$2.82B, yet the company has beaten EPS estimates in recent quarters. Cash flow trends show improvement, with net cash flow turning positive in 2025 at $668M.

The outlook for MRNA hinges on pipeline execution beyond COVID-19, with recent vaccine approvals providing growth catalysts. Investment opportunities include diversification into flu, Ebola, and oncology therapies, but risks persist from high cash burn, competitive pressures, and reliance on successful clinical trials. Analyst sentiment is mixed with a consensus price target of $54.33, below the current price, indicating caution despite some bullish developments.